Fulvestrant
- Generic Name
- Fulvestrant
- Brand Names
- Faslodex, Fulvestrant Mylan
- Drug Type
- Small Molecule
- Chemical Formula
- C32H47F5O3S
- CAS Number
- 129453-61-8
- Unique Ingredient Identifier
- 22X328QOC4
- Background
Fulvestrant is a drug treatment of hormone receptor (HR)-positive metastatic breast cancer in post-menopausal women with disease progression following anti-estrogen therapy. It is an estrogen receptor antagonist with no agonist effects, which works both by down-regulating and by degrading the estrogen receptor. While it is used as monotherapy for the treatme...
- Indication
For the treatment of hormone receptor positive metastatic breast cancer in postmenopausal women with disease progression following anti-estrogen therapy, as monotherapy or in combination with other antineoplastic agents.
- Associated Conditions
- Advanced Breast Cancer, Advanced or Metastatic Breast Cancer
- Associated Therapies
- -
Fulvestrant +/- Akt Inhibition in Advanced Aromatase Inhibitor Resistant Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2013-11-25
- Last Posted Date
- 2022-08-10
- Lead Sponsor
- Velindre NHS Trust
- Target Recruit Count
- 149
- Registration Number
- NCT01992952
- Locations
- 🇬🇧
Royal Blackburn Hospital, Blackburn, United Kingdom
🇬🇧Christie Hospital, Manchester, Greater Manchester, United Kingdom
🇬🇧Ysbyty Gwynedd, Bangor, United Kingdom
Bevacizumab Plus Paclitaxel Optimization Study With Interventional Aintenance Endocrine Therapy in Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2013-11-21
- Last Posted Date
- 2022-08-04
- Lead Sponsor
- Japan Breast Cancer Research Group
- Target Recruit Count
- 160
- Registration Number
- NCT01989780
- Locations
- 🇯🇵
Japan Breast Cancer Research Group, Chuo-ku, Nihonbashi, Koami-cho, Tokyo, Japan
Basket Study of Neratinib in Participants With Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations
- Conditions
- Interventions
- First Posted Date
- 2013-10-01
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- Puma Biotechnology, Inc.
- Target Recruit Count
- 582
- Registration Number
- NCT01953926
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
🇮🇹Istituto Europeo di Oncologia (IEO) I.R.C.C.S., Milano, Italy
🇺🇸Gundersen Center for Cancer and Blood Disorders, La Crosse, Wisconsin, United States
Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery
- Conditions
- Interventions
- First Posted Date
- 2013-10-01
- Last Posted Date
- 2023-08-31
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 1473
- Registration Number
- NCT01953588
- Locations
- 🇺🇸
Mercy Medical Center, Springfield, Massachusetts, United States
🇺🇸Southwest Oncology PC, Durango, Colorado, United States
🇺🇸Epic Care-Dublin, Dublin, California, United States
Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3)
- Conditions
- Interventions
- First Posted Date
- 2013-09-13
- Last Posted Date
- 2024-04-04
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 521
- Registration Number
- NCT01942135
- Locations
- 🇺🇸
Holy Cross Hospital/Michael and Dianne Bienes Comprehensive Cancer Center, Fort Lauderdale, Florida, United States
🇺🇸Sylvester Comprehensive Cancer Center Deerfield Beach, Deerfield Beach, Florida, United States
🇺🇸Memorial Cancer Institute at Memorial Hospital West, Pembroke Pines, Florida, United States
Study of Fulvestrant +/- Everolimus in Post-Menopausal, Hormone-Receptor + Metastatic Breast Ca Resistant to AI
- Conditions
- Interventions
- First Posted Date
- 2013-02-22
- Last Posted Date
- 2018-05-30
- Lead Sponsor
- PrECOG, LLC.
- Target Recruit Count
- 131
- Registration Number
- NCT01797120
- Locations
- 🇺🇸
Marin Cancer Care, Greenbrae, California, United States
🇺🇸SwedishAmerican Regional Cancer Center, Rockford, Illinois, United States
🇺🇸McFarland Clinic, PC, Ames, Iowa, United States
Neratinib +/- Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2012-08-22
- Last Posted Date
- 2022-04-15
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 56
- Registration Number
- NCT01670877
- Locations
- 🇨🇦
BC Cancer Agency, Vancouver, British Columbia, Canada
🇺🇸University of Southern California Keck School of Medicine, Los Angeles, California, United States
🇺🇸University of Miami Hospital and Clinics, Miami, Florida, United States
A Study of LY3023414 in Participants With Advanced Cancer
- First Posted Date
- 2012-08-01
- Last Posted Date
- 2022-04-08
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 156
- Registration Number
- NCT01655225
- Locations
- 🇺🇸
UCLA Medical Center, Los Angeles, California, United States
🇺🇸Penn Presbyterian Medical Center, Philadelphia, Pennsylvania, United States
🇮🇹Azienda Ospedaliero - Universitaria S. Luigi Gonzaga, Orbassano, Torino, Italy
A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi
- Conditions
- Interventions
- First Posted Date
- 2012-07-04
- Last Posted Date
- 2019-01-30
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 432
- Registration Number
- NCT01633060
- Locations
- 🇺🇸
University of Maryland Medical Center Univ Maryland, Baltimore, Maryland, United States
🇺🇸The Methodist Hospital Cancer Center, Houston, Texas, United States
🇺🇸Los Angeles Hematology/Oncology Medical Group Onc Dept., Los Angeles, California, United States
Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor
- Conditions
- Interventions
- First Posted Date
- 2012-06-04
- Last Posted Date
- 2020-08-25
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 1147
- Registration Number
- NCT01610284
- Locations
- 🇺🇸
USC Kenneth Norris Comprehensive Cancer Center Dept.ofNorrisCompCancerCtr (3), Los Angeles, California, United States
🇺🇸University of California at Los Angeles Dept. of UCLA, Los Angeles, California, United States
🇺🇸University of Miami Univ Miami 2, Miami, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.